{
  "id": "602900aa1cb411341a000107",
  "type": "list",
  "question": "Name the three phase 3, randomized, double-blind, placebo-controlled that assessed galcanezumab?",
  "ideal_answer": "Galcanezumab has been assessed in the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2 and REGAIN studies.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32319039"
  ],
  "snippets": [
    {
      "text": "Data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2 and REGAIN studies show that galcanezumab treatment for 3 or 6\u00a0months results in overall reduction in mean monthly migraine headache days in patients with episodic (EVOLVE-1 and EVOLVE-2) and chronic (REGAIN) migraine. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32319039",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "EVOLVE-1, EVOLVE-2, REGAIN"
}